Comparison of Tc-99m Depreotide and In-111 Octreotide in Recurrent Meningioma

Clinical Nuclear Medicine

Volumn 27, Issue 11, 2002, Pages 781-784

  Hellwig, Dirk ^a   Samnick, Samuel ^a   Reif, Johannes ^a   Romeike, Bernd F M ^a   Reith, Wolfgang ^a   Moringlane, Jean R ^a   Kirsch, Carl Martin ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

Meningioma; Recurrence; Somatostatin Receptor Scintigraphy; SPECT

Indexed keywords

DEPREOTIDE TC 99M; PENTETREOTIDE IN 111; RECEPTOR SUBTYPE; SOMATOSTATIN RECEPTOR; DIAGNOSTIC AGENT; DRUG DERIVATIVE; INDIUM 111 OCTREOTIDE; INDIUM-111-OCTREOTIDE; OCTREOTIDE; RADIOPHARMACEUTICAL AGENT; SOMATOSTATIN; TECHNETIUM COMPLEX;

ADULT; ARTICLE; CASE REPORT; FEMALE; HISTOPATHOLOGY; HUMAN; MENINGIOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; PROTEIN EXPRESSION; RECURRENT CANCER; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SOMATOSTATIN RECEPTOR SCINTIGRAPHY; COMPARATIVE STUDY; EYE TUMOR; MIDDLE AGED; SCINTISCANNING; TUMOR RECURRENCE;

EYE NEOPLASMS; FEMALE; HUMANS; MENINGEAL NEOPLASMS; MENINGIOMA; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OCTREOTIDE; ORGANOTECHNETIUM COMPOUNDS; RADIOPHARMACEUTICALS; SOMATOSTATIN;

EID: 0036831843     PISSN: 03639762     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003072-200211000-00005     Document Type: Article

References (12)

1. Osborne AG: Diagnostic Neuroradiology. St Louis: Mosby, 1994, pp 589-601.
2. Schmidt M, Scheidhauer K, Luyken C, et al: Somatostatin receptor imaging in intracranial tumors. Eur J Nucl Med 25:675, 1988.
3. Dotour A, Kumar U, Panetta R, et al: Expression of somatostatin receptor subtypes in human brain tumors. Int J Cancer 76:620, 1998.
4. Bohuslavizki KH, Brenner W, Braunsdorf WE, et al: Somatostatin receptor scintigraphy in the differential diagnosis of meningioma. Nucl Med Comm 17:302, 1996.
5. Blum J, Handmaker H, Rinne N: The utility of a somatostatin-type receptor binding peptide radiopharmaceutical (P829) in the evaluation of solitary pulmonary nodules. Chest 115:224, 1999.
6. Klutmann S, Bohuslavizki KH, Tietje N, et al: Clinical value of 24-hour delayed imaging in somatostatin receptor scintigraphy for meningioma. J Nucl Med 40:1246, 1999.
7. Virgolini I, Leimer M, Handmaker H, et al: Somatostatin receptor subtape specificity and in vitro binding of a novel tumor tracer, 99mTc-P829. Cancer Research 58:1850, 1998.
8. Virgolini I, Traub T, Novotny C, et al: New trends in peptide receptor radioligands. Q J Nucl Med 45:153, 2001.
9. Reubi JC, Waser B, Schaer JC, et al: Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur J Nucl Med 28:836, 2001.
10. Committee for Proprietary Medicinal Products (CPMP): European Public Assessment Report 2065: Scientific Discussion of Depreotide (NeoSPECT): Clinical Pharmacology. London: The European Agency for the Evaluation of Medicinal Products (EAMA), 2000, pp 11-14.
11. Krenning EP, Bakker WH, Kooij PP, et al: Somatostatin receptor scintigraphy with indium-111-DTPA-D-Phe-1-octreotide in man: metabolism, dosimetry and comparison with iodine-123-Tyr-3-octreotide. J Nucl Med 33:652, 1992.
12. Dolinskas CA, Simeone FA: Surgical site after resection of a meningioma. AJNR Am J Neuroradiol 19:419, 1998.